Merozan

Meropenem, the active ingredient in Merozan, is a carbapenem presented as an injectable solution for intravenous use. It provides broad‑spectrum bactericidal activity against Gram‑negative and Gram‑positive pathogens and is indicated for severe infections such as complicated intra‑abdominal infections, hospital‑acquired pneumonia, ventilator‑associated pneumonia, complicated urinary tract infections, meningitis, and severe sepsis or septic shock.

GNH USA supplies Merozan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, sourcing the product from EU manufacturers to ensure quality and regulatory compliance.

Merozan (meropenem) is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: eradicates the causative pathogens and helps resolve intra‑abdominal sepsis. - Hospital‑acquired pneumonia: provides rapid bactericidal activity against resistant respiratory pathogens. - Ventilator‑associated pneumonia: treats ventilator‑related lung infections when other agents are ineffective. - Complicated urinary tract infections: clears resistant Gram‑negative organisms causing pyelonephritis or cystitis. - Meningitis: penetrates the cerebrospinal fluid to eliminate bacterial meningitis agents. - Severe sepsis and septic shock: offers broad coverage for polymicrobial infections in critically ill patients.

Adverse reactions to meropenem may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that may be self‑limiting. - Infusion site reactions: erythema or pain at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal dysfunction or CNS disease. - Anaphylaxis: life‑threatening hypersensitivity reaction requiring immediate treatment. - Clostridioides difficile colitis: severe diarrhea due to disruption of normal gut flora.

Before initiating meropenem therapy, clinicians should consider several precautionary measures to minimize risk. - Renal function: adjust dose in patients with impaired renal clearance. - History of seizures: use cautiously in individuals with pre‑existing seizure disorders. - Hypersensitivity: avoid in patients with known allergy to β‑lactam antibiotics. - Concomitant valproic acid: monitor for reduced valproate levels and possible seizure breakthrough. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: co‑administration may markedly reduce valproate concentrations, risking seizure recurrence. - Aminoglycosides: concurrent use may increase the risk of nephrotoxicity. - Loop diuretics: may enhance ototoxic potential when combined with other ototoxic agents.

Moderate Interactions (Monitor Closely): - Probenecid: may decrease renal clearance of meropenem, requiring dose adjustment. - Anticoagulants (warfarin): monitor INR as meropenem can alter coagulation parameters. - Oral contraceptives: may reduce effectiveness; advise alternative contraception.